Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3872261 | 0.87 | ALDH1A1 (0.56) | HSD11B1KMT2AMEN1NPC1LMNA | |
| SCHEMBL3874145 | 0.83 | FABP4 (0.56) | L3MBTL1LMNA | |
| SCHEMBL3881153 | 0.83 | ALDH1A1 (0.51) | HSD11B1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL3873274 | 0.79 | FABP4 (0.49) | ALDH1A1MAPT | |
| SCHEMBL3874736 | 0.78 | HSD11B1 (0.54) | HSD11B1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL3875950 | 0.77 | TSHR (0.61) | HSD11B1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL3872896 | 0.77 | LMNA (0.52) | HSD11B1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL3876675 | 0.76 | HSD11B1 (0.53) | HSD11B1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL3876662 | 0.76 | HSD11B1 (0.60) | HSD11B1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL3884734 | 0.76 | MAPT (0.51) | KMT2AMEN1NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814846-B1 | 11BETA-HSD1 INHIBITORS | EVOTEC AG (DE) | 2009-04-08 | — | — | EP | disclosed |
| US-20090069323-A1 | 11beta-hsdi inhibitors | EVOTEC AG (DE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069323-A1 | 11beta-hsdi inhibitors | HSD3B1, HSD3B2, HSD11B1 | HSD11B1 3/4885KMT2A 1867/4885MEN1 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.